


# Options for Stage III Melanoma




Making the Decision That's Right for You

## Companion Piece For Canadian Patients



### Options for Stage III Melanoma

Making the Decision That's Right for You



• • •

This is a companion piece for the guide, *Options for Stage III Melanoma: Making the Decision That's Right for You*, which can be downloaded here: (<https://aimwithimmunotherapy.org/canada/>).

This companion piece was developed based on the answers to questions posed by real patients who attended a Facebook Live review of the guide. We hope you find this information helpful to you as you navigate your way through your Stage III melanoma diagnosis.

A resource from the Melanoma International Patient Advocates Coalition.  
This content was created through a collaboration of AIM at Melanoma Foundation and Save Your Skin Foundation.





# Questions and answers

## What is stage III melanoma?

Stage III melanoma is melanoma that has spread (metastasized) from the primary tumour to the regional area. This is in contrast to melanoma that has spread far away to a distant location. In Stage III, melanoma has spread from the original location to the region right around it, or a little further toward the lymph nodes in the region, or to the regional lymph nodes.

You may be familiar with the lymph nodes in your neck, armpit, and groin. As an example, let's say you had a primary melanoma on your upper arm. The lymph nodes that the melanoma would typically travel to first would be under the armpit. If those tested positive for melanoma, it would be considered Stage III disease. You could also have other forms of regional (Stage III) disease. For example, an in-transit metastasis would show up somewhere in the little lymphatic channels that travel away from the primary tumour location but not quite as far as the lymph nodes in the armpit. It would also be Stage III disease if the melanoma spread to the area right around the original primary tumour. This type of spread is sometimes picked up when your doctor performs the wide local excision and is called a microsatellite. So you may hear different terms—nodal disease, satellite, microsatellite, or in-transit disease—to describe melanoma that has spread in the region (Stage III disease).

**Guide Notes:** The last part of the guide contains an in-depth discussion of melanoma staging. Pages 27-28 explain regional (Stage III melanoma) in text and pictures under the heading N (nodal classification).


### N= NODAL CLASSIFICATION

The **nodal** classification in melanoma tells you if any of the melanoma cells have spread from the primary tumor to nearby (regional) lymph nodes or lymph vessels. As shown in Graphic 17, lymph nodes are small, seed-sized structures that contain clumps of immune cells. Their function is to filter the lymphatic fluid. They are found throughout the body, notably in the neck, armpit, and groin. As discussed earlier, cancer cells typically spread from the primary tumor to the nearest lymph node before traveling to other parts of the body.

Lymph node involvement is rated according to a number of factors. One factor is how many lymph nodes are involved. The N classification is divided into three main categories: N0 means there is no lymph node involvement, while N1-3 designations are used for 1 to greater than 4 involved nodes. There are more subgroupings based on whether the nodes are visible to the naked eye/palpable (which means they can be felt by the hand). Some involved nodes are not visible/palpable and are only found by a sentinel lymph node (SLN) biopsy.

SLNs are the first nodes (or a single node) to which lymph fluid flows and to which cancer may move when it leaves the dermis. To perform an SLN biopsy, a doctor will inject a radioactive tracer or dye (marker) into the area near the primary tumor location; the marker will travel via the lymphatics to the sentinel node(s), and this will help the surgeon visualize/identify them. The SLNs will then be removed and examined for cancer cells. Lymph nodes that are identified as having melanoma cells in them, only by performing a SLN biopsy, are classified as occult, since they are not palpable or visible to the naked eye. Generally speaking, when lymph node involvement is occult vs visible or palpable, it marks a better disease course.

Finally, the N classification includes evaluation of satellites, in-transit metastases, and microsatellites. While they may be labeled with different terms, these are all grouped together as intralymphatic regional metastases and are considered regional disease. They all represent small metastases that are close to but separate from the primary tumor. They have not reached the regional (nearby) lymph node. As shown in Graphic 17, when the nodes are “clumped/matted,” meaning the process of spreading has attached them together, that is also a marker of more advanced disease.



Graphic 17. Stage III melanoma. The figure shows the nodes in relationship to the primary melanoma as well as the lymphatics that drain the tissue surrounding the tumor. In the inset, several of the lymph nodes are clumped/matted, which is a marker of more advanced disease. Used with permission from Terese Winslow, LLC.





## Why should I know what specific substage of Stage III melanoma I have?

Stage III melanoma encompasses a wide range of conditions. You may have only one or multiple lymph nodes that contain cancer. Your lymph nodes may be enlarged to the point that your healthcare provider can see or feel them. Or the affected lymph nodes may not be readily apparent—they may only have been detected when the lymph node was biopsied, and the cancer was visible under the microscope. It could be that you had matted or clumped lymph nodes. Alternatively, you may have melanoma in the region between the primary tumour location and the lymph nodes. Your specific substage

of Stage III melanoma is also affected by the characteristics of your primary melanoma—how thick it was and whether or not it was ulcerated, which means part of the upper layer of skin is broken on the top of the melanoma. Ulcerated melanomas have a different disease course (prognosis) than nonulcerated melanomas.

It's important to know this information and which substage of Stage III disease you have, whether it is Stage IIIA, IIIB, IIIC, or IIID. The prognosis differs with each substage.

**Guide Notes:** In addition to pages 27 and 28 of the guide, which explain all of the different elements of the nodal classification system, page 30 contains a table that helps you understand how the primary tumour characteristics and the nodal characteristics can be used to determine your substage. The table also shows the 5-year and 10-year survival rates associated with each substage at the time that the staging system was published.

Your healthcare provider can use this table to help you understand how he/she arrived at your substage and what it means for the predicted course of your disease (prognosis). However, it is important to remember that survival rates do not predict an individual's outcome. Every person and every case are different, and many factors contribute to an individual's survival. It's also important to remember that new and successful treatments have emerged over the last few years, and survival rates are increasing in Stage III melanoma.

Graphic 18. Stage III Melanoma Substaging Criteria.

| Primary Tumor, T Category with Thickness, Ulceration  | Nodal Category  | Stage      | Melanoma-Specific Survival<br>5-Year | Melanoma-Specific Survival<br>10-Year |
|---|---|------------|--------------------------------------|---------------------------------------|
| T1a or T2a: Less than 2.0 mm, <i>not ulcerated</i> OR T1b: Less than 0.8 mm, <i>ulcerated</i> OR 0.8 – 1.00 mm, <i>regardless of ulceration</i> | OR<br>N1a: 1 node found, not visible or palpable (detected by SLN biopsy) OR<br>N2a: 2 or more nodes found, not visible or palpable (detected by SLN biopsy)  | Stage IIIA | 93%                                  | 88%                                   |
| T1a: 2.1 – 4.0 mm, <i>not ulcerated</i> OR T2b: 1.1 – 2.0 mm, <i>ulcerated</i>  | N1a: 1 node found, not visible or palpable (detected by SLN biopsy) OR<br>N2a: 2-3 nodes found, not visible or palpable (detected by SLN biopsy)  |            |                                      |                                       |
| T1a-T3a: Less than 4.0 mm, <i>not ulcerated</i> OR T1b, T2b: Less than 2.0 mm, <i>ulcerated</i>   | OR<br>N1b: 1 node visible/palpable OR<br>N1c: In-transit, satellite, or microsatellite metastases but no disease in the regional lymph node OR<br>N2c: 2-3 nodes, at least 1 visible/palpable   | Stage IIIB | 83%                                  | 77%                                   |
| T0: Primary melanoma not found  | N1b: 1 node visible/palpable OR<br>N1c: In-transit, satellite, or microsatellite metastases but no disease in the regional lymph node   |            |                                      |                                       |
| T1a-T3a: Less than 4.00 mm, <i>not ulcerated</i> OR T1b-T2b: Less than 2.00 mm and <i>ulcerated</i>   | OR<br>N2c: 2-3 nodes, not visible or palpable (detectable by SLN biopsy) OR 1 node visible/palpable with In-transit, satellite, or microsatellite metastases OR<br>N3a: 4 or more nodes, not visible or palpable (detected by SLN biopsy) OR<br>N3b: 4 or more nodes, at least 1 visible or palpable, or any clumped nodes OR<br>N3c: 2 or more nodes, either visible/palpable or not visible/palpable and/or any clumped nodes plus In-transit, satellite, or microsatellite metastases  | Stage IIIC | 69%                                  | 60%                                   |
| T3b: 2.1 – 4.0 mm, <i>ulcerated</i> OR T4a: More than 4.0 mm, <i>not ulcerated</i>  | Any N1, N2, or N3 (any nodal involvement or In-transit, satellite, or microsatellite metastases)  |            |                                      |                                       |
| T4b: More than 4.00 mm, <i>ulcerated</i>  | N1a-N2c: Up to 3 involved nodes, regardless of whether visible/palpable or In-transit, satellite, or microsatellite metastases without regional nodal involvement or only 1 regional node detected  | Stage IIID | 32%                                  | 24%                                   |
| T0: Unknown primary   | N2c: 2-3 nodes, at least 1 visible/palpable OR<br>N2d: 4 or more nodes, not visible or palpable (detectable by SLN biopsy) OR 1 node visible or palpable with In-transit, satellite, or microsatellite metastases OR<br>N3a: 4 or more nodes, at least 1 visible or palpable, or any clumped nodes OR<br>N3b: 2 or more nodes, either visible/palpable or not visible/palpable (detected by SLN biopsy) and/or any clumped nodes plus In-transit, satellite, or microsatellite metastases |            |                                      |                                       |
| T4b: More than 4.00 mm, <i>ulcerated</i>  | N3a: 4 or more nodes, not visible or palpable (detected by SLN biopsy) OR<br>N3b: 4 or more nodes, at least 1 visible or palpable, or any clumped nodes OR<br>N3c: 2 or more nodes, either visible/palpable or not visible/palpable (detected by SLN biopsy) and/or any clumped nodes plus In-transit, satellite, or microsatellite metastases  |            |                                      |                                       |

Graphic 18





## Why is surgery sometimes not enough?

Surgery for stage III disease is sometimes not enough. In Stage III patients, the risk of the disease coming back (recurring) can be high enough that surgical removal of the tumour(s) is not enough. When a lymph node is positive, the melanoma can have access to the rest of the body. It can spread throughout the lymphatic system. The lymphatic system is closely tied to the bloodstream, which travels everywhere throughout the body. So even though the melanoma may have started on your hand, if it gets into the lymphatics, it can spread more

easily. Overall, Stage III patients have about a two-thirds chance of recurrence over 5 years. Thus, there can be a strong rationale for taking medication to prevent the disease from coming back. The higher your substage of Stage III, the greater the risk of recurrence from the disease.

**Guide Notes:** On pages 2-4, the guide addresses the risk for recurrence with Stage III melanoma. It shows survival curves that help you understand why Stage III melanoma is considered high risk and how the risk increases with progressive substages (Stage IIIA, Stage IIIB, Stage IIIC, Stage IIID). It also explains how the tumour can come back even when the surgeon removed all the visible tumour.

### UNDERSTANDING YOUR RISK

Your melanoma stage affects the expected course of your disease. The stages of melanoma can generally be divided into 4 groups:

**Stage 0** is thin melanoma that has not penetrated (invaded) the deeper layers of the skin (in situ).

**Stages I and II** are melanomas that are limited to the skin. These melanomas vary in how thick they are and whether the skin covering the melanoma is **ulcerated** or not. Thicker melanomas and ulcerated melanomas have a higher risk of recurring.

**Stage III** is melanoma that has spread from the original site of your melanoma to 1 or more of the nearby **lymph nodes** or to the nearby skin/tissue in between. Stage III melanoma is divided into 4 groups, A, B, C, and D, as described below. For more information about how these groups are defined, see the section **FURTHER READING ON STAGING**.

**Stage IV** is melanoma that has spread farther than regional lymph nodes, to distant sites such as the lung, liver, or brain.


A survival curve shows how many people can be expected to still be alive, typically anywhere from 1 to 10 years, after their diagnosis. Graphics 1 & 2 show the likelihood of surviving melanoma for 5 or 10 years (melanoma-specific survival). Patients who die from other causes are not included in this number. Remember, survival rates are estimated averages based on past cases and do not necessarily predict your individual survival. Every person and case is different, and many factors contribute to survival. You can discuss these curves with your oncology team.

#### KEY TERMS

**Lymph nodes:** Small, bean-shaped structures containing white blood cells that fight disease. These are located throughout the body but mainly in the armpit, groin, and neck.

**Ulcerated:** Term used to describe when the top layer of skin on a melanoma tumor is broken or missing.

Options for Stage III Melanoma: Making the Decision That's Right for You  
Copyright © 2019 AIM at Melanoma Foundation and Terranova Medica. All Rights Reserved. Document Revised on June 6, 2019



Recently, a German study from the Central Malignant Melanoma Registry (CMMR) evaluated survival rates for 1553 patients with a Stage III melanoma diagnosis from 2000 to 2012. The investigators found generally worse survival rates for patients in this group (among European groups) as compared with those reported by the AJCC stage. For example, in the CMMR, the AJCC group, 5-year survival for Stage IIIa was 80% vs 93%. For Stage IIIb, it was 75% vs 83%. Similar results were seen for 10-year survival and for Stage III in general and in the more advanced substages.

Within the Stage III group, survival rates generally get worse as you go from Stage IIIA to Stage IIID. This is why it is important you and your oncology team discuss your individual stage and risk.

Options for Stage III Melanoma: Making the Decision That's Right for You  
Copyright © 2019 AIM at Melanoma Foundation and Terranova Medica. All Rights Reserved. Document Revised on June 6, 2019

### WHY ARE STAGE III PATIENTS AT HIGH RISK FOR RECURRENCE, AND WHY SHOULD THEY CONSIDER TREATMENT?

High-risk melanoma is a melanoma that has a high likelihood of **recurring** or spreading after the primary tumor has been surgically removed. Overall, patients with Stage III melanoma have a 68% risk of their melanoma recurring within a 5-year period. That means 2 out of 3 people will have a recurrence of their melanoma. For this reason, Stage III patients should consider adjuvant (additional) treatment.

The idea that your cancer might come back or spread may be confusing to you, since you may have been told that "We get it all." Anything that could be seen has been removed, however, what happens to your body you may not see. Unfortunately, there is a chance that some melanoma cells may have broken away from the primary tumor and are still in your body. Although your medical team has done their best to remove all the cancer that is visible, it's not possible to search your entire body for any breakaway cancer cells. Adjuvant therapy is designed to eradicate these breakaway cells—either by interfering with cellular processes

the cells use to grow and multiply or by helping your body's immune system to hunt them down and destroy them. In this way, the cancer may be kept from spreading or coming back. There is a long history of people using adjuvant therapy in other cancers, such as breast cancer. Adjuvant therapy has also been used in the treatment of melanoma for decades, but newer options were developed and did not affect survival. That has changed. Good news is that we have more options for Stage III melanoma, and they are more effective and generally have fewer side effects. The next sections provide you information about these options and, hopefully, can help guide you and your oncology team in deciding what is right for you.

KEY TERMS: **Recurrence:** Melanoma that has returned after treatment.

Options for Stage III Melanoma: Making the Decision That's Right for You  
Copyright © 2019 AIM at Melanoma Foundation and Terranova Medica. All Rights Reserved. Document Revised on June 6, 2019





## What do I need to know before I go to the oncologist?

There are a few pieces of information that your oncology team will need in order to evaluate the options to treat your high-risk melanoma.

First, the team needs all the details about your stage—this can include the pathology report from the original primary as well as all the information from the assessment of your lymph node (example, sentinel lymph node biopsy, surgery, needle biopsy, etc.). They will also need staging scans (imaging) to make sure that the melanoma has not already metastasized farther, meaning it has spread past the lymph nodes to other parts of the body such as in the lung, liver, or bone. Such staging scans could include the use of a positron emission tomography/computer tomography (PET/CT) combination scan, magnetic resonance imaging (MRI), or a CT scan alone. If there are distant metastases, then you would be staged as Stage IV and you and your oncologist would then discuss therapy options specific for that stage.

Another important piece of the puzzle is your *BRAF* status. *BRAF* is a mutation that is present in approximately 50% of cutaneous (skin) melanomas that are tested. If you have melanoma on your hands/feet, your mucosa, or in your eye, different mutations can be involved—we will not be discussing those types of melanoma in this guide. For cutaneous melanoma, the reason it's important to know your *BRAF* status is that there are drug treatments, *BRAF*/MEK inhibitor combinations, that are an option for adjuvant therapy if you have the *BRAF* mutation. But those drugs don't work if you don't have the *BRAF* mutation.

To be tested for the *BRAF* mutation, your pathologist, surgeon, dermatologist, or oncologist must order the test. If your healthcare provider has not ordered the test, you will want to talk with either your surgeon, dermatologist, or oncologist about ordering it.

**Guide Notes:** The guide provides a discussion of *BRAF* testing and treatment for *BRAF*-positive melanoma (pages 5-6).

### OPTIONS FOR STAGE III MELANOMA

You will now be working with your oncology team to figure out what to do next. There are 3 possible options if you have Stage III melanoma. These are targeted therapy, immunotherapy, or active surveillance (no medication involved).

To determine if targeted therapy is an option for you, you will need to have your tumor tested for a marker called *BRAF*. If the *BRAF* test shows that your tumor has the *BRAF* mutation, you are eligible for targeted therapy. But if your tumor does **not** have the *BRAF* mutation, you are not eligible for targeted therapy.

The second option is immunotherapy. Immunotherapy uses medications that are designed to "awaken" your body's own immune system to help fight any remaining cancer cells. You are eligible for immunotherapy regardless of your tumor's *BRAF* status.

Finally, the third option is active surveillance, which means not taking any medication but watching your condition carefully with your oncology team in order to catch your melanoma early if it comes back.

Each of these options is discussed below, with a review of the potential pluses and minuses.

#### TARGETED THERAPY

Both *BRAF* and *MEK* kinases are key protein enzymes that help melanoma cells grow. About half of all melanoma patients have a mutated form of code for the *BRAF* protein in their tumors. This is called having a *BRAF* mutation.

For those patients with a *BRAF* mutation, there is the option to use a combination of oral (by mouth) drugs called dabrafenib and trametinib as an adjuvant therapy. When given together, these drugs can help block these proteins and stop the melanoma from growing. Remember, these drugs only work in people who have the *BRAF* mutation.

**KEY TERMS:** **Mutation:** Change in a structure of a gene that often leads to a change in a protein.

#### IMMUNOTHERAPY

Immunotherapy is a treatment that gives your immune system more power to fight your cancer. Every day, our immune system recognizes dangerous things—cancer cells, foreign invaders like bacteria and some viruses—and hunts them down and destroys them. However, some cancer cells (including some melanoma cells) have ways evading/putting the brakes on your immune system, preventing it from doing its job. In fact, the immune system may not even recognize cancer cells, which might be why they keep growing and multiplying.

Immune checkpoint inhibitors take the brakes off the immune system, allowing it to destroy and destroy cancer cells. PD-1 inhibitors and CTL4 inhibitors are types of immune checkpoint inhibitors. PD-1 inhibitors generally produce fewer and less severe side effects compared with CTL4 inhibitors, such as ipilimumab. Additionally, in a clinical trial nivolumab did a better job of preventing recurrence of Stage III cancer compared with ipilimumab. Nivolumab is a PD-1 inhibitor, while Pembrolizumab is another PD-1 inhibitor.





## What are the options for Stage III melanoma?

There are three options for managing Stage III melanoma: targeted therapy, immunotherapy, and active surveillance. Each are briefly discussed below.

Targeted therapy is a combination of oral medications—a BRAF/MEK inhibitor combination that can be used in patients who have the *BRAF* mutation. Together, these drugs block key protein enzymes that help the melanoma grow.

Immunotherapy treatments give your immune system more power to fight cancer. Currently, immune checkpoint inhibitors—PD-1 inhibitors and CTLA4 inhibitors—are used as adjuvant immunotherapy for melanoma.

Another option is called active surveillance. With active surveillance you are not taking any medicine to prevent the melanoma from coming back, but you are keeping a close eye out for any recurrence. You would go back to your oncologist on a regular basis for monitoring, which would include examination of your skin, a clinical examination to feel for lymph nodes, and additional imaging scans to see if the melanoma has spread further. You might consider active surveillance if you and your oncologist feel like your risk for recurrence is relatively low or if the adjuvant medications are not good options for you.

## Guide Notes

The guide provides a detailed discussion of the options for stage III melanoma on pages 5-10.

**OPTIONS FOR STAGE III MELANOMA**

You will now be working with your oncology team to figure out what to do next. There are 3 possible options if you have Stage III melanoma. These are targeted therapy, immunotherapy, or surgery.

To determine if targeted therapy is an option for you, you will need to have your tumor tested for a marker called *BRAF*. If the *BRAF* test shows that your tumor has the *BRAF* mutation, you are eligible for targeted therapy. If your tumor does not have the *BRAF* mutation, you are not eligible for targeted therapy.

The second option is immunotherapy. Immunotherapy uses medications that are designed to help your immune system recognize and fight against cancer cells. You are eligible for immunotherapy regardless of your tumor's *BRAF* status.

Finally, the third option is surveillance, which means not taking any medication but watching your tumor carefully with your oncologist in order to track your melanoma every 6 months.

Each of these options is discussed below, with a review of the potential pluses and minuses.

**TARGETED THERAPY**

Both *BRAF* and *MET* kinases are key protein enzymes that help melanoma cells grow. About half of all melanoma patients have a mutated form of code for the *BRAF* protein in their tumors. This is called a *BRAF* mutation.

For those patients with a *BRAF* mutation, there is the option to use a combination of oral *BRi* drugs which called *substrates* and transmits an adjuvant therapy. When given together, these drugs can inhibit the protein that melanoma cells use to stimulate melanoma from growing. Remember, these drugs only work in people who have the *BRAF* mutation.

Daab-dab = dabrafenib is approved for patients with Stage II melanoma that has been surgically removed and has tested positive for the *BRAF* mutation. It is not approved for patients who do not have the *BRAF* mutation (wild-type tumor). Therefore, knowing if your tumor has the *BRAF* mutation is important.

Testing for the *BRAF* mutation requires that a sample of your melanoma tumor be processed in a specific way. Ideally, your melanoma should be tested for the *BRAF* mutation at a specialized laboratory. This way, you and your physician can learn about the information needed and to add to reimbursement.

Because using dabrafenib/trametinib for adjuvant therapy is still a relatively new treatment, it is important to discuss the treatment with your oncologist. Bring the treatment to your oncologist and ask him/her to explain the treatment to you. Bring the treatment with them to see if it has been ordered, because you should be re-tested for the *BRAF* mutation before sitting down with your oncologist to discuss your options. Obviously, there are many other factors to consider when deciding if this treatment is right for you. Your oncologist will discuss what happens next. Oncology teams have become more adept at handling these challenging decisions with more experience and treating options.

**ACTIVE SURVEILLANCE**

In some cases, you and your oncologist may decide to use **active surveillance** as the best course of action. Active surveillance is a way of monitoring for melanoma recurrence rather than treating you right away to prevent the melanoma from coming back. Perhaps your tumor has a relatively low risk of recurring, or you have had health problems and are not able to tolerate treatment. In these cases, active surveillance may be best. You won't receive adjuvant treatment but will have regular follow-up exams and tests to detect any spread of the melanoma as it occurs.

Follow-ups may include:

- Physical exams several times a year focusing on your skin and lymph nodes.
- Imaging scans such as an **ultrasound**, an **x-ray**, a **computed tomography (CT)**, a **PET/CT**, or **magnetic resonance imaging (MRI)** to see if there are any signs of melanoma in your lymph nodes or other organs.
- Your oncologist may recommend **genetic testing** if you have had 3 or more invasive melanomas or someone in your family has had melanoma. This testing may allow your provider to further define an appropriate follow-up strategy for you.

**HOW WELL THESE DRUGS WORK**

Oncologists have different ways of looking at how well cancer drugs work. First, they typically look at how many people are still alive after 5 years and after 10 years. This is called the **overall survival**. Second, they look at how long a person lives after the cancer has been diagnosed, regardless of whether the cancer has come back or not. The other way is to look at **relapse-free survival**, which is about how long a person stays free of cancer after it has been treated. This is important because some cancers come back after treatment, even if the person has not been diagnosed with cancer again. For example, a person with Stage III melanoma may have been diagnosed with cancer again, but it may not have been diagnosed directly (head-to-head) with immunotherapy for Stage III melanoma.

**IMMUNOTHERAPY**

**Nivolumab**

For the nivolumab approval, a trial compared nivolumab with ipilimumab. This trial enrolled 905 people who had melanoma in their lymph nodes (Stage III, but excluding Stage IIIa) or distant metastases (Stage IV).<sup>1</sup>

As shown in Graphic 5, after 18 months, 66% of the patients treated with nivolumab were melanoma free, compared with 53% of patients receiving ipilimumab. Overall, there was a 30% improvement in overall survival with nivolumab compared with ipilimumab. Nivolumab was compared with ipilimumab. It's important to remember that this study compared nivolumab with a drug that was not designed to treat melanoma. It was designed to treat bowel cancer. There were also people in this study who had Stage IV melanoma, which is a more advanced disease. More time is needed to see if there will be an improvement in overall survival with nivolumab as compared with ipilimumab.

## IMMUNOTHERAPY (CONTINUED)

### Pembrolizumab

For the pembrolizumab approach, a trial compared pembrolizumab with a placebo (sugar pill) for the treatment of melanoma that had metastasized to the lymph nodes (some Stage IIIA patients are included in this trial). The trial included 1,019 people who had melanoma in the lymph nodes (most Stage IIIA patients). The trial was conducted over 18 months. As shown in Figure 6, at 18 months, 71% of patients treated with pembrolizumab were cancer-free, while 53% of patients treated with the placebo were cancer-free. Overall, there was a 4.7% reduction in the risk of the disease returning or progressing to a more advanced stage compared with the placebo.

The figure consists of two parts. The top part is a bar chart titled 'Figure 6. Results of the trial of pembrolizumab or placebo in patients with completely resected stage III melanoma'. It shows the percentage of patients still cancer-free at 18 months. The 'Pembrolizumab' group is at 71%, and the 'Placebo' group is at 53%. The bottom part is a Kaplan-Meier survival curve showing the percentage of patients still cancer-free over time. The 'Pembrolizumab' curve is consistently higher than the 'Placebo' curve, indicating better survival.

Figure 6. Results of the trial of pembrolizumab or placebo in patients with completely resected stage III melanoma. Adapted from Eggermont 2014.

At a 3-year follow-up, the effect was sustained: 64% of patients treated with pembrolizumab were cancer-free, compared with 44% for those who were treated with placebo. Overall survival was 80% compared with 65%.

### DECISION-MAKING POINTS:

- If you have the BRAF mutation, you may be eligible for either targeted therapy or immunotherapy. You won't know it's better for Stage III patients to receive targeted therapy or immunotherapy.
- For patients who are not eligible for targeted therapy, we don't yet know which patients will respond well to these drugs and which ones won't.
- It is important not to simply look at the snapshots of the data we have given you and try to compare the treatments. That's great, but it's not the whole story. We are also showing you a portion of the data. It's important for a conversation with your oncology team about the data and what it means for you.

Options for Stage III Melanoma: Making the Decision That's Right for You

© 2014 American Society of Clinical Oncology. Reproduced with permission from ASCO. Downloaded from www.asco.org. Copyright © 2014 American Society of Clinical Oncology. All rights reserved.

14



## How long is drug treatment?

Targeted therapies and PD-1 inhibitors can be given for up to a year—as long as you tolerate the side effects and the melanoma has not come back.

**Guide Notes:** See page 17 for a discussion of the how the drugs are given.

## OTHER CONSIDERATIONS

### DRUG ADMINISTRATION

For targeted therapy, you will be taking capsules/tablets twice a day as long as you are tolerating the combination and the melanoma doesn't come back, for up to 1 year.

Nivolumab is given as an intravenous (IV) infusion into your arm, typically at your oncologist's office. The drug is usually given every 2 weeks (but can be given every 4 weeks) and will be continued as long as you tolerate it and the melanoma doesn't come back, for up to 1 year. The infusion lasts for 30 minutes.

Pembrolizumab is given as an IV infusion into your arm, typically at your oncologist's office. The drug is usually given every 3 weeks and will be continued as long as you tolerate it and the melanoma doesn't come back, for up to 1 year. The infusion lasts for 30 minutes.

Now that you have a better understanding of how each treatment is given, here are some factors you may want to consider when discussing with your physician and choosing your treatment option:

#### Targeted Therapy

- How do you feel about having to take "pills" every day?
- Will you remember to take your medication twice a day, every day?
- The trametinib component of targeted therapy must be refrigerated. Would this be an issue for you (for example, having to keep the medication at the proper temperature when traveling)?
- How diligent will you be about taking these pills? They need to be taken on an empty stomach (at least 1 hour before or 2 hours after a meal)

#### Immunotherapy

- Are you willing to go to an infusion center every 2, 3, or 4 weeks?
- Do you have the transportation and the means to get to the infusion center?
- Can you arrange your schedule to be at the infusion center every 2, 3, or 4 weeks?

Many patients expect that pills will have fewer side effects than IV drugs, but that's not always the case. You can get rashes or feel achy with oral drugs just as you do after an IV infusion, and you may be less mentally prepared for side effects from an oral drug than from an infusion.

AIM Options for Stage III Melanoma: Making the Decision That's Right for You  
Copyright © 2019 AIM at Melanoma Foundation and Terranova Medica. All Rights Reserved. Document Revised on June 6, 2019

17

## Do the drug treatments work?

These drugs are effective at reducing your risk of recurrence and improving survival rates in melanoma patients. We are continuously learning about the long-term benefits of these drugs on survival.

**Guide Notes:** See pages 8-10 for a discussion of the data on each of the adjuvant therapies.

### HOW WELL THESE DRUGS WORK

Oncologists have different ways of looking at how well cancer drugs work. First, they typically look at how many people are still alive after 5 years and after 10 years. This is called the **overall survival** benefit, meaning how long a person can live if he or she takes one of these treatments, relative to the person who did not take the treatment. Another way to look at how well a drug works is **recurrence-free survival** (or disease-free survival), which means how long a person may live without having a recurrence of their cancer. It's important to keep in mind that targeted therapy has not been compared directly (head-to-head) with immunotherapy for Stage III melanoma.

#### TARGETED THERAPY

For targeted therapy, a trial compared the dabrafenib + trametinib combination with a placebo (sugar pill). This trial enrolled 870 patients with Stage III melanoma who had the BRAF mutation. Half of the patients received the combination therapy, and half received a placebo.

As shown in Graphic 4, after 2.8 years, 62% of patients receiving the combination were melanoma free, compared with 43% of patients receiving the placebo. Overall, there was a 53% reduction in the risk of the melanoma coming back in patients treated with the combination as compared with the placebo.

Graphic 4. Results of the adjuvant trial of dabrafenib + trametinib vs placebo in patients whose melanoma had been surgically removed and who are at a high risk of recurrence. Adapted from Long et al. 2017.



This benefit is ongoing—recent results show that after 5 years, 52% of the patients treated with the combination were still melanoma-free, compared with 36% of those who had received placebo. However, the investigators were not able to make a definitive statement on the effect on long-term survival, since there were not enough events (deaths) to draw a conclusion.

### IMMUNOTHERAPY

#### Nivolumab

For the nivolumab approval, a trial compared nivolumab with ipilimumab. This trial enrolled 906 people who had melanoma in their lymph nodes (Stage II), but excluding Stage IIIa) or distant metastases (Stage IV) that was removed by surgery.

As shown in Graphic 5, after 18 months, 66% of the patients treated with nivolumab were melanoma free, compared with 53% of patients receiving ipilimumab. Overall, there was a 35% reduction in the risk of the melanoma coming back in patients treated with nivolumab as compared with ipilimumab. It's important to remember that this study compared nivolumab with ipilimumab, which is already known to work in this setting (ipilimumab) and not with a placebo. There were also people in this study who had Stage IV melanoma, which is a more advanced disease. More time is needed to see if there will be an improvement in overall survival with nivolumab as compared with ipilimumab.



At the 4-year follow-up, 52% of the nivolumab-treated patients were cancer free, while 41% of the patients receiving ipilimumab were cancer free.

### IMMUNOTHERAPY (CONTINUED)

#### Pembrolizumab

For the pembrolizumab approval, a trial compared pembrolizumab with a placebo (sugar pill). This trial enrolled 1,019 people who had melanoma in the lymph nodes (some Stage IIIa) or distant metastases (Stage IV) that was removed by surgery. As shown in Graphic 6, at 18 months, 71% of patients treated with pembrolizumab were cancer free, while 53% of patients treated with the placebo were cancer free. Overall, there was a 43% reduction in the risk of the melanoma coming back in patients treated with pembrolizumab as compared with the placebo.



At a 3-year follow-up, the effect was sustained: 64% of patients treated with pembrolizumab were cancer free, compared with 44% for those who were treated with placebo. Overall survival was not reported.

### DECISION-MAKING POINTS:

If you have the BRAF mutation, you may be eligible for either targeted therapy or immunotherapy. We don't know if it is better for Stage III patients to receive targeted therapy or immunotherapy.

For both immunotherapy and targeted therapy, we don't yet know which patients will respond well to these drugs and which ones won't.

It is important not to simply look at the snapshots of the data we have given you and try to compare the treatments. These trials were done in different groups of people at different times, and these trials were set up differently. We are also only showing you a portion of the data. It's important to have a conversation with your oncology team about the data and what it means for you.





## What are the side effects of these drugs?

With the BRAF/MEK inhibitors, about 97% of patients will have some kind of side effect. So although it's easy to take this combination at home, you may experience side effects of some kind. The most common are fevers—and they can be pretty high, in the 103°F range; fatigue; and nausea. An itchy rash can develop. Other side effects as described in the guide. Your oncologist can adjust the medicine and reduce the dose if some of these side effects tend to be more severe.

With immunotherapy, the most common side effect is fatigue. The drugs work by revving up the immune system, so you can develop autoimmune problems, like an inflammation of the colon, a rash, liver inflammation, endocrine problems, pulmonary issues, etc. These can happen any time during the course of your therapy or even after your therapy, and they can progress and become serious. But they can generally be treated quite effectively. So it's important to inform your care team about any changes in how you feel because some of the immune-related side effects can start off very subtly. It's best to treat them early.


**Guide Notes:** See pages 11-16 for a discussion of the side effects of the drugs.

### THE SIDE EFFECTS OF THE DRUGS

#### TARGETED THERAPY

Targeted therapy is associated with a range of side effects. In the clinical trial that led to dabrafenib + trametinib reported in the adjuvant setting, 97% of patients who received dabrafenib + trametinib reported having at least 1 side effect. Common side effects of dabrafenib + trametinib are listed in Graphic 7 and Graphic 8.


Graphic 7. Common side effects associated with dabrafenib + trametinib and the percentage of patients reporting them in the clinical trials. These side effects are listed in descending order from the most common to the least common. From the manufacturer's prescribing information.



AIM Options for Stage III Melanoma: Making the Decision That's Right for You  
Copyright © 2019 AIM at Melanoma Foundation and Terranova Medica. All rights reserved. Document Revised on June 4, 2019

Targeted therapies tend to cause "nuisance" side effects, not typically as serious as those associated with immunotherapy but nonetheless challenging (eg, fevers can make the patient very uncomfortable). Some of the side effects—particularly the more serious ones—can be managed with either a decrease in the dose of the drug or discontinuing the drug entirely if the side effect is not treatable. The range of serious side effects is shown in Graphic 9 and Graphic 10 below. Of note, the fever commonly associated with dabrafenib + trametinib can get worse and lead to serious complications if it is not treated promptly.

In the follow-up study of the dabrafenib/trametinib combination used for adjuvant therapy, there were no differences in the incidence or severity of serious side effects between the treatment and placebo-treated patients.



Graphic 9. Serious side effects associated with dabrafenib + trametinib reported in the clinical trials. These side effects are listed in descending order from the most common to the least common. Adapted from the manufacturer's prescribing information.

#### HOW ARE THESE SIDE EFFECTS MANAGED?

With targeted therapy, sometimes an individual side effect can be managed with specific medications (for example, acetaminophen for fever) and supportive care (increasing fluids in patients with fever). Other times, these side effects can be managed with either a decrease in the dose of the drug or discontinuing the drug entirely if the side effect is not treatable after the symptoms go away. Sometimes when the drug or drugs are resumed, it is at a lower dosage. In some rare cases, the drug may need to be permanently discontinued. Once patients stop taking the drugs, the drugs wash out of the body within a few months and the symptoms typically stop.

A safety concern of targeted therapy is the potential for drug-drug interactions, since these drugs are broken down by a common enzyme that breaks down many medications as well. If you are taking any medications that may cause heart arrhythmias or you are on hormonal contraceptives, since this can cause drug-drug interactions with the targeted therapy. Drug-drug interactions are less of an issue with immunotherapies, since they are not broken down by the same enzymes along with most prescription drugs.




Graphic 10. Body image showing serious side effects associated with dabrafenib + trametinib.

AIM Options for Stage III Melanoma: Making the Decision That's Right for You  
Copyright © 2019 AIM at Melanoma Foundation and Terranova Medica. All rights reserved. Document Revised on June 4, 2019


#### IMMUNOTHERAPY

Immunotherapy is associated with a range of side effects. In the nivolumab and pembrolizumab clinical trials, most patients had side effects that should be linked to the therapy. Severe or life-threatening side effects were reported in 20% of patients. Graphic 11 lists the common side effects associated with nivolumab; Graphic 12 shows those associated with pembrolizumab, and Graphic 13 shows a body image with these side effects.

Graphic 11. Common side effects associated with nivolumab and the percentage of patients experiencing them in the clinical trials. These side effects are listed in descending order from the most common to the least common. Adapted from the manufacturer's prescribing information.



Graphic 12. Common side effects associated with pembrolizumab and the percentage of patients experiencing them in the clinical trials. These side effects are listed in descending order from the most common to the least common. Adapted from the manufacturer's prescribing information.



As mentioned earlier, immunotherapy works by unleashing the body's immune system to fight the cancer. For that reason, the immune system may get revved up and attack any organ or tissue system. This means if you receive immunotherapy, you can have a range of side effects affecting any part of your body. Also, because these side effects are caused by changes in your immune system, they can occur at any time during treatment or even after treatment has ended.

Potentially serious side effects of immunotherapy can become life-threatening. These side effects are shown in Graphic 14. Graphic 15 shows a body image with the organs and organ systems affected by immunotherapy. This list is not complete—as mentioned above, any organ or body system can be affected.

Graphic 14. Serious side effects that can occur with immunotherapy. Lists of adverse events are listed from clinical trials that may be higher in the real-world setting. These are generally grouped from most common to least common.

| Potentially serious side effect  | Overall occurrence rate (% of patients affected) | Severe or life-threatening occurrence rate (% of patients affected) |
|--|--|---|
| <b>Skin problems</b> (such as rash and itching)  | Up to 40%  | Less than 2%  |
| <b>Intestinal problems</b>   |  |   |
| Diarrhea, which can lead to dehydration  | 8% to 20%  | Less than 2%  |
| Colitis (inflammation of the colon)  | 1% to 3%   | Less than 1%  |
| <b>Hormonal problems</b>   |  |   |
| Thyroid (most common)  | 3% to 10%  | Less than 1%  |
| Other endocrinopathies (involving the pituitary, thyroid, adrenal, or pituitary/center of the brain) | Less than 3%                                     | Less than 3%  |
| <b>Liver problems</b> (stated predominantly)   | Less than 10%                                    | Less than 1%  |
| Liver problems (stated predominantly)  | 1% to 6%   | 1% to 2%  |
| <b>Neurologic problems</b> (including pain in the brain)   | Less than 3%                                     | Less than 1%  |
| <b>Kidney problems</b>   | Less than 2%                                     | Less than 1%  |

Graphic 14. Serious side effects that can occur with immunotherapy. Lists of adverse events are listed from clinical trials that may be higher in the real-world setting. These are generally grouped from most common to least common.

AIM Options for Stage III Melanoma: Making the Decision That's Right for You  
Copyright © 2019 AIM at Melanoma Foundation and Terranova Medica. All rights reserved. Document Revised on June 4, 2019

#### HOW ARE THESE SIDE EFFECTS MANAGED?

With immunotherapy, reducing the dosage is not generally recommended. The management of side effects is similar to the management of targeted therapy and managing the side effect. In many cases, corticosteroids are used to quiet the immune system, after which immunotherapy can be restarted. But in severe cases, the drug may need to be discontinued.

#### DECISION-MAKING POINTS:

- Immunotherapy may cause hormonal side effects that are manageable, but you may need to stay on hormone replacement for life. Many of other side effects are reversible, although there are some cases in which patients have permanent problems with the liver, kidneys, or other organs. Also, side effects can occur long after the immunotherapy regimen is completed.

AIM Options for Stage III Melanoma: Making the Decision That's Right for You  
Copyright © 2019 AIM at Melanoma Foundation and Terranova Medica. All rights reserved. Document Revised on June 4, 2019





## Will these drugs affect my ability to have children?

These drugs may cause fetal harm. Therefore, the general recommendation is for couples to avoid pregnancy while one of them is taking any of these medicines—whether it's a man or a woman. So while you're on therapy, make sure that you're using two birth control methods. These can be condoms, female contraceptive, whatever that is for you. However, if you are a woman taking targeted therapy, you need to be careful with oral contraceptives because they may interact with your medicine. While experts don't believe these drugs have a direct long-term effect on fertility, the immunotherapies may affect the hormone system long term because of a

potential hormonal effect, so some patients have described difficulty getting pregnant for the year or so after they stopped treatment.

Most clinics will tell you not to conceive until at least six months after immunotherapy is stopped. Now, targeted therapy clears from your system a little bit faster, and the manufacturer recommends that you don't get pregnant for at least four months after therapy.

Before considering any next steps in family planning, consult your health care team.

**Guide Notes:** See page 19 for a discussion of fertility/family planning with these therapies.

### FERTILITY/FAMILY PLANNING

#### Pregnancy Prevention

Whether you are a woman of childbearing age or a man who is sexually active, it is important that you use effective birth control while on treatment and for the specified time thereafter. These medications can cause fetal harm. People taking dabrafenib + trametinib should use an effective nonhormonal birth control method such as a condom, diaphragm, or spermicide during treatment and for 4 months after the last dose. Hormonal birth control (pills) is not recommended because of the potential for interaction with this drug combination. For nivolumab or pembrolizumab, you should use an effective method of birth control during treatment and for 6 months after the last dose of therapy.

#### Fertility/Family Planning

Fertility and family planning can be important issues to consider. Little is specifically known about the impact of these drugs on fertility. What is known is that once targeted therapy is discontinued, there are generally no long-term side effects, and the drugs are out of your system relatively quickly. If you use effective birth control and don't conceive for 4 months after you stop treatment, it is unlikely the medication would have a long-term effect on fertility.

With immunotherapy, fertility questions are more complex because of the potential of long-term impact on the immune system from these drugs in both men and women. Side effects could occur (including hormonal changes such as pituitary or thyroid problems) that could impact fertility, but this has not been well studied. Again, at the very least, you should avoid trying to conceive for at least 6 months after you stop treatment.

It's important to have a frank conversation with your oncology team about your family planning issues prior to starting treatment. You might also want to consider seeing a fertility specialist who is familiar with these issues in cancer patients. You may wish to discuss whether you can freeze some of your eggs/sperm before treatment if you are considering trying to conceive later. Your oncology team might have some names of specialists who can help.





## Is one approach better than the other?

Not necessarily. Your oncologist will work with you on deciding your specific treatment plan. A lot of factors will be considered:

- Your substage and risk for recurrence
- Your *BRAF* status
- Any existing autoimmune conditions
- Your overall health
- The safety of the drugs
- Convenience/quality of life
- Fertility/Family planning

**Guide Notes:** See pages 20-22 for the worksheets to help you weigh your options. You can complete these worksheets with your healthcare team to evaluate the options and select the approach that is best for you.

**WEIGHING THE DIFFERENT OPTIONS**

The following worksheets are intended for you and your medical oncologist to use to evaluate whether targeted therapy, immunotherapy, or active surveillance is the best approach for your melanoma that is at high risk of recurrence. These worksheets will help you weigh the potential pros and cons of each option.

**Worksheet 1: Targeted Therapy**

| Factor to Consider                     | My Thoughts | 1 | 2 | 3 | 4 | 5 |
|--|-------------|---|---|---|---|---|
| My tumor status ( <i>BRAF</i> )        |             |   |   |   |   |   |
| Effectiveness of the drug              |             | 1 | 2 | 3 | 4 | 5 |
| Side effects                           |             | 1 | 2 | 3 | 4 | 5 |
| Convenience of receiving the treatment |             | 1 | 2 | 3 | 4 | 5 |
| Quality of life                        |             | 1 | 2 | 3 | 4 | 5 |
| Financial considerations               |             | 1 | 2 | 3 | 4 | 5 |
| Fertility/family planning              |             | 1 | 2 | 3 | 4 | 5 |
| Other factors                          |             | 1 | 2 | 3 | 4 | 5 |

Not At All Important  
Slightly Important  
Important  
Fairly Important  
Very Important

AIM Options for Stage III Melanoma: Making the Decision That's Right for You  
Copyright © 2014 AIM at Melanoma Foundation and Terranova Medica. All Rights Reserved. Document Revised on June 6, 2015

**Worksheet 2: Immunotherapy**

| Factor to Consider                     | My Thoughts | 1 | 2 | 3 | 4 | 5 |
|--|-------------|---|---|---|---|---|
| My tumor status ( <i>BRAF</i> )        |             |   |   |   |   |   |
| Effectiveness of the drug              |             | 1 | 2 | 3 | 4 | 5 |
| Side effects                           |             | 1 | 2 | 3 | 4 | 5 |
| Convenience of receiving the treatment |             | 1 | 2 | 3 | 4 | 5 |
| Quality of life                        |             | 1 | 2 | 3 | 4 | 5 |
| Financial considerations               |             | 1 | 2 | 3 | 4 | 5 |
| Fertility/family planning              |             | 1 | 2 | 3 | 4 | 5 |
| Other factors                          |             | 1 | 2 | 3 | 4 | 5 |

Not As Important  
Slightly Important  
Important  
Fairly Important  
Very Important

AIM Options for Stage III Melanoma: Making the Decision That's Right for You  
Copyright © 2014 AIM at Melanoma Foundation and Terranova Medica. All Rights Reserved. Document Revised on June 6, 2015

**Worksheet 3: Active Surveillance**

| Factor to Consider                         | My Thoughts | 1 | 2 | 3 | 4 | 5 |
|--|-------------|---|---|---|---|---|
| My tumor status ( <i>BRAF</i> )            |             |   |   |   |   |   |
| No treatment side effects                  |             | 1 | 2 | 3 | 4 | 5 |
| Anxiety/concern about not having treatment |             | 1 | 2 | 3 | 4 | 5 |
| Likelihood that the cancer might come back |             | 1 | 2 | 3 | 4 | 5 |
| Quality of life                            |             | 1 | 2 | 3 | 4 | 5 |
| Financial considerations                   |             | 1 | 2 | 3 | 4 | 5 |
| Fertility/family planning                  |             | 1 | 2 | 3 | 4 | 5 |
| Other factors                              |             | 1 | 2 | 3 | 4 | 5 |

Not At All Important  
Slightly Important  
Important  
Fairly Important  
Very Important

**Final Thoughts**

We hope you found this guide to be helpful in evaluating your options for your Stage III melanoma. Our goal has been to empower you to work with your oncology team to make the best decision for you. We have included in the list below other resources that you may want to consult as you evaluate your options. Being informed puts you in the best position to have an active role in this important decision.

AIM Options for Stage III Melanoma: Making the Decision That's Right for You  
Copyright © 2014 AIM at Melanoma Foundation and Terranova Medica. All Rights Reserved. Document Revised on June 6, 2015

The development of this companion piece was supported by an unrestricted educational grant from Bristol Myers Squibb.